You are here: Home: Audio Program Guide: LCU 3 | 2007 Audio: LCU 3 | 2007

   
  To listen to individual tracks, click the audio icon.
To download tracks, right-click on the one you wish to download.
 
Johnston, MD Bruce E Johnson, MD
Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

  
  Click here to download entire interview  
Track 1 Response to tyrosine kinase inhibitor (TKI) therapy based on EGFR mutation status
Track 2 Mechanism of action of the TKIs
Track 3 Factors influencing EGFR mutation status
Track 4 Techniques for assessing EGFR mutations
Track 5 Response to TKIs in nonsmokers without EGFR mutations
Track 6 Assessing EGFR mutations using analysis of free DNA in circulating blood
Track 7 Clinical trials incorporating the assessment of EGFR mutations
Track 8 Clinical use of EGFR mutation testing
Track 9 Use of erlotinib in patients with EGFR mutations
Track 10 Treatment algorithm for the management of metastatic NSCLC
Track 11 Tolerability of carboplatin/paclitaxel and bevacizumab
Track 12 Approach to second-line therapy for metastatic NSCLC
Track 13 AVAiL trial: Cisplatin/gemcitabine with or without bevacizumab in patients with chemotherapy-naïve,
advanced or recurrent nonsquamous NSCLC
Track 14 ECOG-E1505: Adjuvant chemotherapy with or without bevacizumab in completely resected Stage IB
to IIIA NSCLC		 audio
Track 15 Tolerability of adjuvant bevacizumab audio
Track 16 Adjuvant therapy for Stage IB NSCLC audio
Track 17 Nanoparticle albumin-bound (nab) paclitaxel in lung cancer audio
Track 18 Data with vandetanib (ZD6474) in lung cancer audio
Track 19 Tolerability of vandetanib audio
Track 20 Phase II randomized trial of vandetanib and docetaxel audio
Track 21 Ongoing trials with vandetanib audio
Track 22 Prophylactic cranial radiation therapy for extensive-stage small cell lung cancer audio
 
Socinski, MD Mark A Socinski, MD
Associate Professor of Medicine
Multidisciplinary Thoracic Oncology Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina
  
  Click here to download entire interview  
Track 1 Adjuvant chemotherapy as a treatment option for Stage IB NSCLC
Track 2 Adjuvant chemotherapy in Stage IB NSCLC: Update of CALGB-9633
Track 3 Selection of a chemotherapy regimen in the adjuvant setting
Track 4 Clinical management of inadequate assessment of the mediastinum
Track 5 Clinical use of adjuvant erlotinib in nonsmokers
Track 6 Impact of rash and dermatologic conditions on the acceptability of adjuvant erlotinib
Track 7 HOG trial of consolidation docetaxel in patients with Stage III disease
Track 8 Current chemoradiation therapy approaches for Stage III disease
Track 9 Role of surgery in patients with Stage III disease
Track 10 Selecting patients with Stage IV disease for treatment with bevacizumab
Track 11 Duration of therapy with bevacizumab in patients with Stage IV disease
Track 12 AVAiL trial of cisplatin/gemcitabine with or without bevacizumab
Track 13 Continuation of bevacizumab beyond disease progression
Track 14 Use of bevacizumab in combination with erlotinib
Track 15 Clinical trial incorporating bevacizumab and erlotinib with chemoradiation therapy in Stage III NSCLC Audio
Track 16 Earlier incorporation of anti-EGFR therapy in the treatment of oligosmokers and never smokers Audio
Track 17 Development of nab paclitaxel in lung cancer Audio
Track 18 Feasibility study of adjuvant carboplatin/docetaxel in NSCLC Audio
Track 19 Use of adjuvant carboplatin/docetaxel Audio
Track 20 Timing in the administration of second-line therapy Audio
Track 21 Treatment selection for second- and third-line therapy Audio
 
Wakelee, MD Heather A Wakelee, MD
Assistant Professor of Medicine
Division of Oncology
Stanford School of Medicine
Stanford, California

  
  Click here to download entire interview  
Track 1 HOG LUN 01-24: Cisplatin/etoposide in combination with concurrent radiation therapy with or without consolidation docetaxel for inoperable Stage III NSCLC
Track 2 Clinical use of biologic agents for patients treated with chemoradiation therapy
Track 3 Perspective on the AVAiL trial results with bevacizumab in combination with cisplatin/gemcitabine
Track 4 Clinical use of bevacizumab with chemotherapy in metastatic NSCLC
Track 5 Toxicity data from the AVAiL trial
Track 6 ECOG-E1505: Adjuvant chemotherapy with or without bevacizumab in completely resected Stage IB
to IIIA NSCLC
Track 7 Safety concerns with adjuvant bevacizumab
Track 8 Response from community-based oncologists to ECOG-E1505
Track 9 MRC-LU22: Surgery with or without neoadjuvant chemotherapy for patients with resectable NSCLC
Track 10 Lung cancer in nonsmokers
Track 11 Erlotinib in enriched populations audio
Track 12 Selection of therapy for patients with metastatic NSCLC audio